MAVENCLAD TABLET

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

CLADRIBINE

Saatavilla:

EMD SERONO, A DIVISION OF EMD INC., CANADA

ATC-koodi:

L04AA40*

INN (Kansainvälinen yleisnimi):

CLADRIBINE

Annos:

10MG

Lääkemuoto:

TABLET

Koostumus:

CLADRIBINE 10MG

Antoreitti:

ORAL

Kpl paketissa:

1/4/5/6/7/8

Prescription tyyppi:

Prescription

Terapeuttinen alue:

IMMUNOSUPPRESSIVE AGENTS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0124270002; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2017-11-30

Valmisteyhteenveto

_MAVENCLAD_
_®_
_ (cladribine) Product Monograph _
_Page 1 of 39 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
MAVENCLAD®
Cladribine
10 mg Tablet, oral
Selective Immunosuppressant
TREATMENT WITH MAVENCLAD SHOULD BE INITIATED AND SUPERVISED BY
NEUROLOGISTS EXPERIENCED IN THE
TREATMENT OF PATIENTS WITH MS AND WHO HAVE FULLY FAMILIARIZED
THEMSELVES WITH THE EFFICACY AND
SAFETY PROFILE OF MAVENCLAD.
EMD Serono, a Division of EMD Inc., Canada
2695 North Sheridan Way, Suite 200
Mississauga, Ontario L5K 2N6
www.emdserono.ca
EMD Serono is a business of Merck KGaA, Darmstadt, Germany
Date of Initial Authorization:
November 29, 2017
Date of Revision:
October 7, 2021
Submission Control Number: 249245
MAVENCLAD is a trademark of Merck KGaA, Darmstadt, Germany or its
affiliates.
_MAVENCLAD_
_®_
_ (cladribine) Product Monograph _
_Page 2 of 39 _
RECENT MAJOR LABEL CHANGES
4.1 Dosing Considerations
10/2021
7 Warnings and Precautions, Hepatic/Biliary/Pancreatic
10/2021
7 Warnings and Precautions, Immune, Hypersensitivity
10/2021
2 Contraindications
11/2020
4.1 Dosing Considerations
11/2020
7 Warnings and Precautions, General, Carcinogenesis and
Mutagenesis, Sexual Function/Reproduction
11/2020
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics (< 18 years of
age)..............................................................................
4
1.2
Geriatrics (> 65 years of age)
..............................................................................